<DOC>
	<DOCNO>NCT01265121</DOCNO>
	<brief_summary>Sleep apnea common situation affect 80 % acromegalic patient . This disease link disturbance carbohydrate metabolism increase rate diabetes . The objective trial ass ( euglycemic hyperinsulinemic clamp ) impact treatment sleep apnea , continuous positive air pressure device ( CPAP ) , insulin resistance .</brief_summary>
	<brief_title>Sleep Apnea Syndrome Acromegaly : Impact Treatment Carbohydrates Metabolism .</brief_title>
	<detailed_description />
	<mesh_term>Apnea</mesh_term>
	<mesh_term>Sleep Apnea Syndromes</mesh_term>
	<mesh_term>Sleep Apnea , Obstructive</mesh_term>
	<mesh_term>Insulin Resistance</mesh_term>
	<mesh_term>Acromegaly</mesh_term>
	<criteria>Acromegalic patient Moderate severe sleep apnea Using somatostatin analogue maximum dosage possible least 6 month Unstable angina high risk stroke Hepatic renal insufficiency Uncontrolled diabetes Seizures Steroids use Uncontrolled hormonal deficiency</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2010</verification_date>
	<keyword>Acromegaly</keyword>
	<keyword>Insulin resistance</keyword>
	<keyword>Euglycemic Clamp</keyword>
	<keyword>Somatostatin analogue</keyword>
</DOC>